<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[77, 78] fluorouracil/epirubicin/cyclophosphamide<br></td>
<td width=33%>
[6, 7] FEC<br>[77, 81] fluorouracil/epirubicin/cyclophosphamide (FEC)<br>[95, 96] FEC(100<br>[108, 114] dose-dense FEC regimens.<br>[121, 122] FEC(75<br>[143, 144] pegfilgrastim<br>[199, 200] FEC(75<br>[213, 214] FEC(90<br>[239, 241] (FEC(90<br>[261, 262] FEC(90<br>[299, 301] (FEC(90<br>[320, 321] FEC(75<br>[322, 323] FEC(90<br></td>
<td width=33%>
[2, 15] two dose-dense FEC regimens with growth factor support for adjuvant therapy<br>[41, 45] epirubicin to adjuvant chemotherapy<br>[77, 81] fluorouracil/epirubicin/cyclophosphamide (FEC)<br>[92, 97] standard chemotherapy and FEC(100)<br>[106, 114] two intermediate dose-dense FEC regimens.<br>[118, 126] six cycles of FEC(75) or FEC(90)<br>[143, 146] pegfilgrastim 6 mg<br>[199, 200] FEC(75<br>[213, 214] FEC(90<br>[239, 241] (FEC(90<br>[261, 262] FEC(90<br>[299, 301] (FEC(90<br>[320, 321] FEC(75<br>[322, 323] FEC(90<br></td>
</tr>
